What is the recommended treatment for prurigo?

Treatment for Prurigo

For prurigo nodularis (chronic prurigo), start with dupilumab as first-line systemic therapy, as it is the only FDA-approved treatment and demonstrates superior efficacy in reducing both pruritus and nodular lesions with minimal side effects. 1, 2, 3

Initial Management Approach

Topical Therapy (First-Line for Localized Disease)

• Topical corticosteroids (moderate-to-high potency) are the foundation of initial treatment 4, 5
• Topical calcineurin inhibitors for sensitive areas or maintenance therapy 6
• Avoid crotamiton cream - proven ineffective in controlled trials 7
• Avoid topical capsaicin and calamine lotion for generalized prurigo (though capsaicin may help in uraemic pruritus specifically) 7
• Consider topical doxepin for up to 8 days maximum, limited to 10% body surface area and 12 g daily due to contact dermatitis risk 7

Systemic Therapy Algorithm

For Moderate-to-Severe Disease:

1. Dupilumab (First-Line) 1, 2, 3

   • Only FDA-approved medication for prurigo nodularis
   • Targets IL-4/IL-13 pathways
   • Reduces pruritus intensity (NRS ≤3 as target) and achieves lesion healing (IGA-S 0/1)
   • Fewest side effects among systemic options
   • Superior evidence base with multiple clinical trials

2. If Dupilumab Fails or Is Unavailable:

   • JAK inhibitors (baricitinib, tofacitinib) - emerging evidence shows robust antipruritic effects 5, 3, 6
   • Thalidomide - highly effective but limited by peripheral neuropathy and muscle pain with long-term use 3
   • Pregabalin or gabapentin - effective for neuropathic component, but long-term use limited by nerve/muscle pain 3

3. Adjunctive Systemic Options:

   • Non-sedating antihistamines (fexofenadine 180 mg, loratadine 10 mg, or cetirizine 10 mg) before sedating agents 7
   • SSRIs (paroxetine, fluvoxamine) or mirtazapine for refractory cases 7
   • Naltrexone or aprepitant (neurokinin-1 receptor antagonist) 7
   • Consider H1 + H2 antagonist combination (e.g., fexofenadine + cimetidine) 7

Phototherapy

• Narrowband UVB (NB-UVB) is effective for widespread disease 7
• Can be used as monotherapy or combined with systemic agents
• Particularly useful when systemic therapy is contraindicated

Treat-to-Target Criteria (SWITCH Algorithm)

Evaluate treatment success at regular intervals using these specific targets: 8

• Itch control: NRS ≤3 (from baseline ≥7)
• Lesion healing: IGA-S score 0/1 (clear or almost clear)
• Quality of life: Improvement in DLQI and sleep quality

If targets are NOT met within 12-16 weeks, switch therapy rather than continuing ineffective treatment.

Critical Pitfalls to Avoid

• Do not use long-term sedating antihistamines - they predispose to dementia and should be avoided except in palliative care (Strength B recommendation) 7
• Do not rely on antihistamines alone - prurigo is predominantly non-histaminergic; antihistamines are adjunctive at best 7
• Do not use cetirizine for uraemic pruritus - proven ineffective 7
• Do not use gabapentin for hepatic pruritus - contraindicated 7
• Avoid topical capsaicin for generalized prurigo - systematic reviews do not support its use except in uraemic pruritus 7

Disease-Specific Modifications

If Underlying Cause Identified:

Iron deficiency: Iron replacement (Strength C) 7

Hepatic pruritus:

• First-line: Rifampicin (Strength A)
• Second-line: Cholestyramine
• Third-line: Sertraline
• Fourth-line: Naltrexone/nalmefene 7

Uraemic pruritus:

• Optimize dialysis, correct calcium-phosphate balance, treat anemia with erythropoietin
• BB-UVB is highly effective (Strength A)
• Consider capsaicin cream, topical calcipotriol, or oral gabapentin 7

Lymphoma-associated: Cimetidine, carbamazepine, gabapentin, or mirtazapine; oral corticosteroids for incurable disease 7

Polycythemia vera: Cytoreductive therapy, aspirin, interferon-α, SSRIs, or phototherapy 7

Combination Therapy Considerations

Dupilumab + topical corticosteroids is a rational combination targeting both systemic inflammation and local disease 2. Conventional agents may be combined, though no head-to-head trials exist comparing combination vs. monotherapy efficacy 2.

Emerging Therapies

Multiple novel agents are in clinical trials targeting neuroimmune pathways, including IL-31 antagonists, additional JAK inhibitors, and kappa opioid receptor agonists 1, 6. These show promise but are not yet available for routine use.